Ac Immune(NASDAQ) ACIU

Current Price$2.30

Market Cap$228.99M

Since IPO (2016)-86%

5 Year-70%

1 Year+9%

1 Month-6%

Ac Immune last closing stock price
Metric	Price	Date
Last close	USD 2.25	2026-07-20

Ac Immune stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-8.16%	USD 2.45	2026-07-13
1 month	-6.25%	USD 2.40	2026-06-18
3 month	-21.6%	USD 2.87	2026-04-21
Year to date	-28.34%	USD 3.14	2025-12-31
1 year	+8.7%	USD 2.07	2025-07-18
3 year	-26.23%	USD 3.05	2023-07-21
5 year	-70.39%	USD 7.60	2021-07-21
Since inception	-85.63%	USD 15.66	2016-09-23

Ac Immune Financials at a Glance

Market Cap

$228.99M

Revenue (TTM)

CHF 3.70M

Net Income (TTM)

-CHF 66.22M

EPS (TTM)

-$0.82

P/E Ratio

-2.74

Dividend

$0.00

Beta (Volatility)

1.13 (Average)

Dividend

$0.00

Beta (Volatility)

1.13 (Average)

Price

$2.30

Volume

2,092

Open

$2.22

Price

$2.30

Volume

2,092

Open

$2.22

Previous Close

$2.30

Daily Range

$2.22 - $2.32

52-Week Range

$2.03 - $4.00

Estimated Earnings Date

Aug 4, 2026

Dividend

$0.00

Beta (Volatility)

1.13 (Average)

Price

$2.30

Volume

2,092

Open

$2.22

Previous Close

$2.30

Daily Range

$2.22 - $2.32

52-Week Range

$2.03 - $4.00

Estimated Earnings Date

Aug 4, 2026

ACIU News

Two people participating in a telehealth session

ACIU: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ac Immune

AC Immune S.A. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents and diagnostic tools for neurodegenerative diseases caused by protein misfolding. The company utilizes its proprietary platforms to create vaccines, antibodies, and small molecules targeting conditions such as Alzheimer's disease.

Products and Services

Crenezumab: A monoclonal antibody in Phase II trials for Alzheimer's disease
ACI-24: An anti-Abeta vaccine candidate in Phase II evaluation for Alzheimer's disease
ACI-35: An anti-Tau vaccine candidate that has completed Phase Ib clinical assessment

Growth Outlook

Strong pipeline with multiple candidates in advanced clinical stages
Strategic partnerships with industry leaders enhance research capabilities
Focus on neurodegenerative diseases presents significant market opportunities

Financial Highlights

Recent quarterly revenue of 1,119,000 CHF, showing growth potential
Cash and short-term investments total 74,797,000 CHF, providing operational flexibility
Net income for Q1 2026 reported at -14,801,000 CHF, reflecting ongoing investment in R&D

AC Immune S.A. is positioned at the forefront of biotechnology, addressing critical unmet needs in neurodegenerative disease treatment. The company's innovative approach, combined with a robust pipeline and strategic partnerships, underscores its potential for growth in a rapidly evolving market. Recent financial data indicates a commitment to research and development, which is essential for long-term success in the biotechnology sector. The significant cash reserves provide a buffer for continued investment in clinical trials and product development, making AC Immune an intriguing option for investors interested in the biotechnology field.

AI Generated • Jul 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

122

CEO

Andrea Pfeifer, PhD

Website

www.acimmune.com

Headquarters

Lausanne, VD 1015, CH

ACIU Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1749.00%

Net Income Margin

-1788.79%

Return on Equity

-123.98%

Return on Capital

-139.17%

Return on Assets

-48.19%

Earnings Yield

-36.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$228.99M

Shares Outstanding

101.77M

Volume

2.09K

Avg. Volume

275.78K

Financials (TTM)

Gross Profit

CHF 3.70M

Operating Income

-CHF 64.75M

EBITDA

-CHF 64.45M

Operating Cash Flow

-CHF 50.39M

Capital Expenditure

-CHF 538.16K

Free Cash Flow

-CHF 50.92M

Cash & ST Invst.

CHF 74.80M

Total Debt

CHF 4.30M

Ac Immune Performance Analysis

Ac Immune annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	CHF 4,120,138	N/A
2023	2023-12-31	CHF 16,470,229	299.7%
2024	2024-12-31	CHF 31,009,431	88.3%
2025	2025-12-31	CHF 4,302,299	-86.1%

Ac Immune sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	31.9%
Q3	2025-09-30	-28.1%
Q4	2025-12-31	-64.0%
Q1	2026-03-31	231.1%

Ac Immune annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	CHF -0.89	-16.8%
2023	2023-12-31	CHF -0.71	-19.6%
2024	2024-12-31	CHF -0.58	-18.6%
2025	2025-12-31	CHF -0.84	45.2%

Ac Immune sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-10.5%
Q3	2025-09-30	23.8%
Q4	2025-12-31	12.5%
Q1	2026-03-31	-7.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

CHF 1.12M

+13.0%

Gross Profit

CHF 1.12M

+13.0%

Gross Margin

100.00%

N/A

Market Cap

$228.99M

N/A

Market Cap/Employee

$1.88M

N/A

Employees

122

N/A

Net Income

-CHF 14.80M

+22.2%

EBITDA

-CHF 14.74M

+19.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

CHF 74.80M

-48.6%

Total Debt

CHF 4.30M

-16.8%

Accounts Receivable

CHF 230.00K

-75.1%

Inventory

CHF 0.00

N/A

Long Term Debt

CHF 3.48M

-16.0%

Short Term Debt

CHF 825.00K

-20.1%

Return on Assets

-48.19%

N/A

Return on Invested Capital

-1.43%

N/A

Free Cash Flow

CHF 0.00

+100.0%

Operating Cash Flow

CHF 0.00

+100.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CLLSCellectis S.A.

CLLSCellectis S.A.$2.69+3.46%

AMRNAmarin Corporation plc

AMRNAmarin Corporation plc$13.93+2.43%

LYELLyell Immunopharma, Inc.

LYELLyell Immunopharma, Inc.$13.11+1.47%

ALDXAldeyra The

ALDXAldeyra The$1.75+2.94%

MREOMereo BioPharma Group plc

MREOMereo BioPharma Group plc$0.31+0.20%

SLNSilence Therapeutics plc

SLNSilence Therapeutics plc$10.85+3.43%

CTNMContineum Therapeutics, Inc.

CTNMContineum Therapeutics, Inc.$13.90+2.73%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$7.66+0.11%

TAT&T

TAT&T$22.26+0.01%

NOKNokia

NOKNokia$10.63+0.05%

MARAMara Holdings

MARAMara Holdings$12.25+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$15.28+0.01%

JOBYJoby Aviation

JOBYJoby Aviation$7.66+0.03%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$123.54+0.03%

Questions About ACIU

What is the current price of Ac Immune?

Ac Immune is trading at $2.30 per share.

What is the 52-week range for Ac Immune?

Over the past 52 weeks, Ac Immune has traded between $2.03 and $4.00.

How much debt does Ac Immune have?

As of the most recent reporting period, Ac Immune reported total debt of CHF 5.36M.

How much cash does Ac Immune have on hand?

Ac Immune reported CHF 23.86M in cash and cash equivalents in its most recent financial results.

What is Ac Immune’s dividend yield?

Ac Immune does not currently have a dividend yield.

Ac Immune(NASDAQ) ACIU

Ac Immune Financials at a Glance

ACIU News

Why AC Immune Stock Zoomed Almost 15% Higher Today

Why Shares of AC Immune Jumped This Week

Here's Why AC Immune Stock Is Surging Today

Why AC Immune Stock Surged Today

Why AC Immune Stock Is Crashing Today

Here's Why AC Immune Jumped Higher Today

Why AC Immune SA Is Imploding

Here's Why AC Immune SA Rose as Much as 21.6% Today

ACIU: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Ac Immune

ACIU Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Ac Immune Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ACIU

What is the current price of Ac Immune?

What is the 52-week range for Ac Immune?

How much debt does Ac Immune have?

How much cash does Ac Immune have on hand?

What is Ac Immune’s dividend yield?

Premium Investing Services